Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 9/20 | 0.41 |
| ▸ | BRAF | P15056 | 5/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798990 | 0.91 | RAF1 (0.41) | RAF1BRAFKDRCHEK2CSNK2A1 | |
| SCHEMBL5734205 | 0.85 | RAF1 (0.41) | RAF1BRAFKDRHDAC11CSNK1A1 | |
| SCHEMBL4173612 | 0.81 | RAF1 (0.55) | USP2TSHRMAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL4166869 | 0.72 | POLB (0.61) | RAF1BRAFKDRCHEK2CSNK2A1 | |
| SCHEMBL4172140 | 0.71 | KDR (0.43) | RAF1BRAFKDRCSNK1A1CSNK1D | |
| SCHEMBL5733440 | 0.70 | KDR (0.56) | RAF1BRAFKDRCSNK1A1CSNK1D | |
| SCHEMBL4161807 | 0.69 | KDR (0.52) | RAF1BRAFKDRCSNK1A1CSNK1D | |
| SCHEMBL4166878 | 0.69 | MGAM (0.49) | SMN1; SMN2RAF1KDRCSNK1A1CSNK1D | |
| SCHEMBL5733146 | 0.68 | KDR (0.58) | RAF1BRAFKDRCSNK1A1CSNK1D | |
| SCHEMBL4161466 | 0.68 | KDR (0.53) | RAF1BRAFKDRCSNK1A1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | claimed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | claimed |
| EP-1675849-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-07-05 | — | — | EP | claimed |
| WO-2005042520-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-05-12 | — | — | WO | claimed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1675849-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005042520-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082404-A1 | BENZIMIDAZOLES | TIE1, KDR, FLT1 | USP2 1030/4885TSHR 1822/4885MAPK1 1136/4885 |
| US-20070066660-A1 | Benzimidazolyl derivatives | TIE1, ECE2, ABL1 | USP2 523/4885TSHR 1960/4885MAPK1 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.